In this cohort study, we assessed the real-world safety and effectiveness of the implementation of neoadjuvant/adjuvant biosimilar trastuzumab compared to Herceptin among Ontario patients with HER2+ breast cancer. The gene discussed is ERBB2; the disease is breast cancer.